Latest Inovio Pharmaceuticals Inc. Stories
BLUE BELL, Pa., Feb. 27, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced that CEO Dr. J. Joseph Kim will present an overview of the company at the Cowen & Company 33rd Annual Health Care Conference taking place March 4-6 at the Boston Marriott Copley Place. Inovio PresentationWednesday, March 611:20-11:50 a.m. ESTA live and archived webcast of the presentation will be available on Inovio's homepage. About Inovio Pharmaceuticals, Inc. Inovio...
NEW YORK, Feb. 11, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that their February 7th RetailInvestorConferences.com presentation is now available for on-demand viewing. LINK: www.retailinvestorconferences.com > red "register/ watch event now" button Inovio's presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks. About Inovio Pharmaceuticals,...
NEW YORK, Feb. 5, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at RetailInvestorConferences.com. DATE: February 7, 2013TIME: 3:00 PM ESTLINK: www.retailinvestorconferences.com > red "register / watch event now" button This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall...
BLUE BELL, Pa., Feb. 4, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will present an overview of the company at the 15th Annual BIO CEO and Investor Conference taking place February 11-12 at the Waldorf Astoria in New York City. Inovio PresentationFebruary 129:30-10:00 a.m. ESTA live and archived webcast of the presentation will be available on Inovio's homepage. About Inovio Pharmaceuticals, Inc. Inovio is...
BLUE BELL, Pa., Jan. 9, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) and its development partner VGX International, Inc. (KSE: 011000) will move Inovio's hepatitis C (HCV) DNA vaccine into a phase I/IIa clinical trial by the end of 2013. This advancement is based on outstanding results of a preclinical study which demonstrated for the first time that a multi-antigen SynCon® HCV vaccine can generate robust T-cell responses not only in the blood but, more...
WASHINGTON and BLUE BELL, Pa., Jan. 7, 2013 /PRNewswire/ -- The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies. Researchers will test whether a novel vaccine approach that combines genetically engineered DNA with an innovative vaccine delivery technology called electroporation could induce an immune response in humans...
BLUE BELL, Pa., Dec. 20, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO), which is revolutionizing vaccines to combat cancers and infectious diseases, announced today that Dr. J. Joseph Kim, President and CEO, will be presenting a corporate overview of the company at the Biotech Showcase 2013 investor conference. Biotech Showcase 2013 January 7-9Parc 55 Wyndham-Union SquareSan Francisco, CA Inovio PresentationTuesday, January 810:30AM PST A live and archived...
BLUE BELL, Pa., Dec. 10, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) reported interim results of a phase I trial that showed that a single dose of its H1N1 universal SynCon® flu vaccine followed with a dose of a seasonal flu vaccine generated protective immune responses in 40% of trial subjects compared with a 20% response rate in elderly patients who received the seasonal flu vaccine alone. This interim data is a significant step in developing a more...
BLUE BELL, Pa., Dec. 6, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses...
BLUE BELL, Pa., Nov. 26, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon® DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV...
